Kovack Advisors Inc. purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 28,242 shares of the biopharmaceutical company’s stock, valued at approximately $2,023,000. Gilead Sciences comprises about 1.0% of Kovack Advisors Inc.’s portfolio, making the stock its 17th biggest position.
Other institutional investors have also recently modified their holdings of the company. BlackRock Inc. raised its holdings in Gilead Sciences by 1.9% during the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares in the last quarter. Vanguard Group Inc. raised its holdings in Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares in the last quarter. FMR LLC raised its holdings in Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after purchasing an additional 258,005 shares in the last quarter. Northern Trust Corp raised its holdings in Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after purchasing an additional 116,780 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in shares of Gilead Sciences by 1.0% in the 2nd quarter. Franklin Resources Inc. now owns 14,516,058 shares of the biopharmaceutical company’s stock valued at $1,027,436,000 after acquiring an additional 136,884 shares during the period. Institutional investors own 77.96% of the company’s stock.
A number of equities analysts have recently commented on GILD shares. Leerink Swann reaffirmed a “market perform” rating and issued a $80.00 target price (down from $83.00) on shares of Gilead Sciences in a report on Thursday, February 22nd. Credit Suisse Group reaffirmed a “buy” rating and issued a $82.00 target price on shares of Gilead Sciences in a report on Thursday, December 7th. Zacks Investment Research cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. ValuEngine raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Finally, Argus cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and lifted their target price for the company from $73.25 to $73.77 in a report on Monday, November 13th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and a consensus price target of $87.75.
Gilead Sciences, Inc. (GILD) opened at $81.06 on Tuesday. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $89.54. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67. The firm has a market cap of $105,740.62, a price-to-earnings ratio of 9.45, a P/E/G ratio of -1.86 and a beta of 1.24.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the consensus estimate of $1.67 by $0.11. The company had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The business’s revenue was down 18.7% on a year-over-year basis. During the same period in the previous year, the firm earned $2.70 EPS. equities analysts anticipate that Gilead Sciences, Inc. will post 6.21 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be given a dividend of $0.57 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a dividend yield of 2.81%. The ex-dividend date of this dividend is Thursday, March 15th. Gilead Sciences’s payout ratio is presently 59.77%.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.